RenovoRx (RNXT) Other Accumulated Expenses (2021 - 2026)
RenovoRx (RNXT) posted Other Accumulated Expenses of $204000.0 for Q1 2026, up 1940.0% sequentially from $10000.0 in Q4 2025, and up 3980.0% YoY from $5000.0 in Q1 2025.
RenovoRx (RNXT) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
RenovoRx has reported Other Accumulated Expenses for 6 years, with the latest figure at $204000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 3980.0% year-over-year to $204000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204000.0 (up 3980.0% YoY) and the FY2025 annual result came in at $10000.0, up 25.0% from the prior year.
- Other Accumulated Expenses advanced to $204000.0 in Q1 2026 per RNXT's latest filing, from $10000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $211000.0 in Q3 2023 and troughed at $5000.0 in Q4 2022.
- A 5-year average of $66176.5 and a median of $37000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses plunged 96.71% in 2025, then soared 3980.0% in 2026.
- Over 5 years, Other Accumulated Expenses stood at $5000.0 in 2022, then surged by 1280.0% to $69000.0 in 2023, then sank by 88.41% to $8000.0 in 2024, then climbed by 25.0% to $10000.0 in 2025, then soared by 1940.0% to $204000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $204000.0, $10000.0, and $83000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 69,000.00 |
| Sep 30, 2023 | 211,000.00 |
| Jun 30, 2023 | 29,000.00 |
| Mar 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Sep 30, 2022 | 69,000.00 |
| Jun 30, 2022 | 37,000.00 |
| Mar 31, 2022 | 111,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Sep 30, 2021 | 8,000.00 |